title: Local T cell responses induce widespread MHC expression. Evidence that IFN-gamma induces its own expression in remote sites.
abstract: Local inflammation induces increased expression of MHC and other genes in the affected tissue because of the paracrine effects of cytokines such as IFN-gamma. We previously reported that one such process--local allograft rejection--was accompanied by increased expression of MHC in a remote tissue, namely kidney. To explore how local inflammation affects gene expression in remote tissues, we studied MHC, beta 2-microglobulin, and IFN-gamma expression in mice undergoing either of two T cell-dependent localized inflammatory processes: rejection of an ascites tumor allograft, and skin sensitization by oxazalone. As assessed by binding of radiolabeled mAb and by immunohistology, each stimulus increased MHC expression in many remote tissues, including liver, heart, pancreas, and kidney. This was associated with increases in steady state mRNA for class I, class II, and beta 2-microglobulin. MHC induction was inhibited by the in vivo administration of cyclosporine or anti-IFN-gamma mAb and did not occur in nude mice, confirming the key role of IFN-gamma released from T cells. When we examined tissues of mice with these localized inflammatory lesions for IFN-gamma mRNA levels by polymerase chain reaction, we found that IFN-gamma steady state mRNA levels were increased in the spleen and, more surprisingly, in the kidney, and in uninvolved skin. Moreover, anti-IFN-gamma inhibited the induction of IFN-gamma mRNA in the kidney, suggesting that IFN-gamma expression was induced by IFN-gamma in an autoregulatory fashion. Thus the systemic MHC induction accompanying local T cell-mediated inflammation reflects the release of IFN-gamma from the site of inflammation, but may be amplified by the ability of IFN-gamma to induce its own expression in remote tissues. This self-amplification of IFN-gamma may contribute to the ability of local inflammation to induce extensive systemic effects.
authors.affiliation: Department of Medicine, University of Alberta, Edmonton, Canada.
authors.forename: P F
authors.initials: PF
authors.lastname: Halloran
authors.forename: P
authors.initials: P
authors.lastname: Autenried
authors.forename: V
authors.initials: V
authors.lastname: Ramassar
authors.forename: J
authors.initials: J
authors.lastname: Urmson
authors.forename: S
authors.initials: S
authors.lastname: Cockfield
mesh_terms: D000818:Animals; D016572:Cyclosporine / Q000494:pharmacology; D015870:Gene Expression; D005805:Genes, MHC Class I; D005802:Genes, MHC Class II; D006084:Graft Rejection; D007371:Interferon-gamma / Q000502:physiology*; D007668:Kidney / Q000276:immunology; D008099:Liver / Q000276:immunology; D008285:Major Histocompatibility Complex; D051379:Mice; D008815:Mice, Inbred Strains; D008819:Mice, Nude / Q000276:immunology; D009206:Myocardium / Q000276:immunology; D009368:Neoplasm Transplantation; D010081:Oxazolone / Q000276:immunology; D012867:Skin / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D010081:Oxazolone; D007371:Interferon-gamma; D016572:Cyclosporine